阿帕替尼联合放疗对HeLa细胞Ki-67表达的影响及与生长抑制相关性研究

Effect of Apatinib Combined with Radiotherapy on the Expression of Ki-67 in HeLa Cells and Its Correlation with Growth Inhibition

目的探讨阿帕替尼联合放射治疗(简称放疗)对宫颈癌HeLa细胞Ki-67表达的影响,以及与肿瘤生长抑制率的相关性。方法将建立的BALB/c-nu荷瘤鼠随机分为对照组、单纯放疗组和阿帕替尼联合放疗组(联合组)。免疫组织化SP法检测Ki-67表达。结果联合放疗组和放疗组Ki-67阳性表达率分别为(14. 40±2. 72)%和(66. 78±5. 01)%,较对照组的(92. 83±4. 04)%,分别降低84. 49%和28. 06%(P <0. 05)。联合组比放疗组降低78. 44%(P <0. 05)。联合组和放疗组肿瘤体积分别为(1 156. 38±110. 75) mm3和(1 641. 60±153. 15) mm3,较对照组的(2 437. 03±223. 16) mm3,分别缩小52. 55%和32. 64%(P <0. 05),联合放疗组比放疗组缩小29. 56%(P <0. 05)。联合放疗组肿瘤生长抑制率(TGIR)为57. 00%,显著高于放疗组的34. 83%(P <0. 05)。结论阿帕替尼联合放疗可明显抑制宫颈癌Ki-67阳性表达率,提高肿瘤生长抑制率。建议其可用于Ki-67高表达率的宫颈癌患者。

Objective To investigate the effect of apatinib combined with radiotherapy on the expression of Ki-67 in HeLa cells of cervical cancer and its correlation with the tumor growth inhibition rate(TGIR).Methods BALB/c-nu tumor-bearing mice were randomly divided into the control group,simple radiotherapy group and apatinib combined radiotherapy group(combined group).The Ki-67 expression was detected by immunohistochemical streptavidin peroxidase(SP)method.Results The positive expression rates of Ki-67 in the combined group and the radiotherapy group were(14.40±2.72)%and(66.78±5.01)%,which decreased 84.49%and 28.06%compared to(92.83±4.04)%in the control group(P<0.05),the combined group decreased 78.44%compared to the radiotherapy group(P<0.05).The tumor volumes of in the combined group and the radiotherapy group were(1 156.38±110.75)mm3 and(1 641.60±153.15)mm3,which reduced 52.55%and 32.64%compared to(2 437.03±223.16)mm3 in the control group(P<0.05),the combined group reduced 29.56%compared to the radiotherapy group(P<0.05).The TGIR of the combined group was 57.00%,which was significantly higher than 34.83%of the radiotherapy group(P<0.05).Conclusion Apatinib combined with radiotherapy can obviously inhibit the positive expression rates of Ki-67 for cervical cancer and improve TGIR.It is recommended that this therapeutic regimen can be used for cervical cancer patients with high expression of Ki-67.